Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Van Cutsem, E. | - |
dc.contributor.author | Muro, K. | - |
dc.contributor.author | Cunningham, D. | - |
dc.contributor.author | Bodoky, G. | - |
dc.contributor.author | Sobrero, A. | - |
dc.contributor.author | Cascinu, S. | - |
dc.contributor.author | Ajani, J. | - |
dc.contributor.author | Oh, S. C. | - |
dc.contributor.author | Al-Batran, S. E. | - |
dc.contributor.author | Wainberg, Z. A. | - |
dc.contributor.author | Wijayawardana, S. R. | - |
dc.contributor.author | Melemed, S. | - |
dc.contributor.author | Ferry, D. | - |
dc.contributor.author | Hozak, R. R. | - |
dc.contributor.author | Ohtsu, A. | - |
dc.date.accessioned | 2021-08-31T08:56:18Z | - |
dc.date.available | 2021-08-31T08:56:18Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/57530 | - |
dc.description.abstract | Background: The RAINBOW trial showed that second-line ramucirumab with paclitaxel prolongs overall survival (OS) and progression-free survival (PFS) compared with placebo plus paclitaxel for treatment of advanced gastric/gastroesophageal junction cancer. Plasma samples were collected from patients during the trial and tested to identify predictive and prognostic biomarkers. Patients and methods: Circulating factors in plasma samples from mutually exclusive subsets of RAINBOW patients were assayed using: Intertek assays (24 markers, 380 samples, 57% of patients) and Lilly-developed assay (LDA) platform (5 markers, 257 samples, 39% of patients). Time-trend plots were generated for each marker from the Intertek assays. Baseline patient data were dichotomized into low- and high-marker subgroups. Markers were analyzed for predictive effects using interaction models and for prognostic effects using main-effects models. Results: The Intertek and LDA populations were representative of the full trial population. Plasma levels of VEGF-D and PlGF increased from baseline levels during treatment, then declined after treatment discontinued. Angiopoietin-2 exhibited a decrease during treatment, then increased after treatment discontinuation. No clear time trend was evident with the other markers. Analyses of baseline biomarker expression and its relationship with efficacy variables found no biomarker was predictive for efficacy outcomes, including VEGF-D. However, CRP, HGF, ICAM-3, IL-8, SAA, and VCAM-1 were identified as potential prognostic markers with low baseline levels corresponding to longer OS and PFS. Conclusions: Pharmacodynamic and prognostic relationships were found from the exploratory biomarker analyses in RAINBOW; however, no predictive markers for ramucirumab in gastric cancer were identified in this trial. (C) 2019 The Author(s). Published by Elsevier Ltd. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | GROWTH-FACTOR | - |
dc.subject | SUPPORTIVE CARE | - |
dc.subject | VEGF-C | - |
dc.subject | TUMOR | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | ANGIOPOIETIN-2 | - |
dc.subject | EXPRESSION | - |
dc.subject | MARKERS | - |
dc.subject | PLUS | - |
dc.title | Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, S. C. | - |
dc.identifier.doi | 10.1016/j.ejca.2019.10.026 | - |
dc.identifier.scopusid | 2-s2.0-85078745947 | - |
dc.identifier.wosid | 000514572100015 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, v.127, pp.150 - 157 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.title | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.volume | 127 | - |
dc.citation.startPage | 150 | - |
dc.citation.endPage | 157 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | GROWTH-FACTOR | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | VEGF-C | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | ANGIOPOIETIN-2 | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | MARKERS | - |
dc.subject.keywordPlus | PLUS | - |
dc.subject.keywordAuthor | Ramucirumab | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Gastroesophageal junction cancer | - |
dc.subject.keywordAuthor | Biomarker | - |
dc.subject.keywordAuthor | Predictive | - |
dc.subject.keywordAuthor | Prognostic | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.